Publications by authors named "H Hirosawa"

Background: Extracellular adenosine 5'-triphosphate (ATP) acts as a signaling molecule in the peripheral nerves, regulating myelination after nerve injury. The present study examined whether the cerebrospinal fluid (CSF) ATP levels in patients with Guillain-Barré syndrome (GBS) and chronic inflammatory demyelinating polyneuropathy (CIDP) are related to disease severity.

Methods: CSF ATP levels in 13 patients with GBS and 18 patients with CIDP were compared with those in a control group of 16 patients with other neurological diseases (ONDs).

View Article and Find Full Text PDF

Background: Functional gastrointestinal disorders (FGIDs), including functional dyspepsia (FD) and irritable bowel syndrome (IBS), are characterized by chronic and recurrent gastrointestinal symptoms. Clinically, FD and IBS often resemble gastrointestinal dysmotility caused by autoimmune autonomic neuropathy. We examined the seropositive frequency of autoantibodies against ganglionic nicotinic acetylcholine receptors (gnAChRs) in patients presenting with FGIDs.

View Article and Find Full Text PDF

Background: Presarcopenia is a common complication of chronic liver disease. However, the relationship between serum zinc concentration and presarcopenia in patients with chronic liver disease remains unclear. Herein, we examined whether serum zinc concentration could predict presarcopenia in patients with chronic liver disease.

View Article and Find Full Text PDF

An 83-year-old man with hepatocellular carcinoma developed muscle weakness, ptosis, and dyspnea 3 weeks after receiving atezolizumab. Soon after, mechanical ventilation was initiated, which was followed by marked blood pressure spikes. The levels of creatine kinase and troponin-I were significantly elevated, and acetylcholine receptor antibodies were positive.

View Article and Find Full Text PDF
Article Synopsis
  • - A 68-year-old man with small-cell lung cancer developed paraneoplastic neurological syndrome (PNS) with symptoms like ataxia and chorea while being treated with durvalumab.
  • - Treatment with steroids led to a decrease in anti-CRMP-5 antibodies and improvement of his neurological symptoms and brain MRI findings.
  • - After restarting durvalumab, he experienced severe neurological adverse events, highlighting the need for caution when resuming immune checkpoint inhibitors in PNS patients.
View Article and Find Full Text PDF